

# 1 **Illness duration and symptom profile in a large cohort of** 2 **symptomatic UK school-aged children tested for SARS-** 3 **CoV-2**

4  
5 Erika Molteni PhD<sup>1\*</sup>, Carole H. Sudre PhD<sup>1,2,3\*</sup>, Liane S. Canas PhD<sup>1</sup>, Sunil S. Bhopal PhD<sup>4</sup>,  
6 Robert C. Hughes MPH MB ChB<sup>5</sup>, Michela Antonelli PhD<sup>1</sup>, Benjamin Murray MSc<sup>1</sup>, Kerstin  
7 Kläser MSc<sup>1</sup>, Eric Kerfoot PhD<sup>1</sup>, Liyuan Chen MSc<sup>1</sup>, Jie Deng PhD<sup>1</sup>, Christina Hu BA<sup>6</sup>,  
8 Somesh Selvachandran MEng<sup>6</sup>, Kenneth Read BSc<sup>6</sup>, Joan Capdevila Pujol PhD<sup>6</sup>, Alexander  
9 Hammers PhD<sup>1,7</sup>, Tim D. Spector PhD<sup>8</sup>, Sebastien Ourselin PhD<sup>1</sup>, Claire J. Steves PhD<sup>8</sup>,  
10 Marc Modat PhD<sup>1</sup>, Michael Absoud PhD<sup>9,10</sup>, Emma L. Duncan PhD<sup>8,10</sup>.

- 11  
12 **1.** School of Biomedical Engineering & Imaging Sciences, King's College London,  
13 London, UK.  
14 **2.** MRC Unit for Lifelong Health and Ageing, Department of Population Health Sciences,  
15 University College London, London, UK.  
16 **3.** Centre for Medical Image Computing, Department of Computer Science, University  
17 College London, London, UK.  
18 **4.** Population Health Sciences Institute, Faculty of Medical Sciences, Newcastle  
19 University, Newcastle upon Tyne, Tyne and Wear, UK.  
20 **5.** Department of Population Health, Faculty of Epidemiology & Population Health,  
21 London School of Hygiene & Tropical Medicine, Keppel Street, London, UK.  
22 **6.** Zoe Global, London, UK.  
23 **7.** King's College London & Guy's and St Thomas' PET Centre, London, UK.  
24 **8.** Department of Twin Research and Genetic Epidemiology, King's College London,  
25 London, UK.  
26 **9.** Children's Neurosciences, Evelina London Children' Hospital, St Thomas' Hospital,  
27 King's Health Partners, Academic Health Science Centre, London, UK.  
28 **10.** Department of Women and Children's Health, Faculty of Life Sciences and Medicine,  
29 School of Life Course Sciences, King's College London, London, UK.

30 \* Equal contribution

31

32

## 33 **Corresponding Author:**

34 Emma L. Duncan, MBBS, FRACP, FRCP, PhD

**NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

35 Department of Twin Research and Genetic Epidemiology, and Department of Women and  
36 Children's Health  
37 King's College London,  
38 WC2R 2LS, Strand, London, UK.  
39 emma.duncan@kcl.ac.uk

40

41 **Key words**

42 Long COVID; ongoing symptomatic COVID-19; post-COVID-19 syndrome; SARS-CoV-2  
43 prolonged infection; school-children; paediatric COVID-19.

44 **Word count:** 5975

45 **Number of Tables:** 2

46 **Number of Figures:** 4

47 **Number of Supplementary Tables:** 4

48 **Number of Supplementary Figures:** 6

49

## 50 **Research in context**

51

52

53 **Evidence before this study:** SARS-CoV-2 in children is usually asymptomatic or manifests  
54 as a mild illness of short duration. However, anecdotal cases have raised concerns of  
55 prolonged illness in children, with no clear resolution of symptoms several weeks after onset,  
56 as is observed in some adults. How common this might be in children, the clinical features of  
57 such prolonged illness in children, and how it might compare with illnesses from other  
58 respiratory viruses (and with general population prevalence of these symptoms) is unclear.

59

60 **Added value of this study:** We provide systematic description of COVID-19 in school-aged  
61 children. Our data, collected in a digital surveillance platform through one of the largest  
62 citizen science initiatives, show that long illness duration after SARS-CoV-2 infection in  
63 school-aged children does occur, but is uncommon. Only a small proportion of children have  
64 illness beyond four weeks; and the symptom burden in these children usually decreases  
65 over time. Most children resolve all symptoms by eight weeks, providing reassurance about  
66 long term outcomes. Importantly, symptom burden does not outnumber that observed in long  
67 illness due to causes other than SARS-CoV-2 infection.

68

69 **Implications of all the available evidence:**

70 Our results confirm that COVID-19 illness in children and adolescents is resolved in the  
71 community, after short duration, low symptom burden and with no need of hospitalization in  
72 most cases. Our findings also highlight that allocation of appropriate resources will be  
73 necessary for any child with prolonged illness, whether due to SARS-CoV-2 infection or  
74 other illness. Our study provides timely and critical data to inform discussions around the  
75 impact and implications of the pandemic on UK paediatric healthcare resource allocation.

76

## 77 **Abstract**

78

### 79 **Background**

80 In children, SARS-CoV-2 is usually asymptomatic or causes a mild illness of short duration.  
81 Persistent illness has been reported; however, its prevalence and characteristics are  
82 unclear. We aimed to determine illness duration and characteristics in symptomatic UK  
83 school-aged children tested for SARS-CoV-2 using data from the COVID Symptom Study,  
84 the largest citizen participatory epidemiological study to date.

85

### 86 **Methods**

87 Data from 258,790 children aged 5-17 years were reported by an adult proxy between 24  
88 March 2020 and 22 February 2021. Illness duration and symptom profiles were analysed for  
89 all children testing positive for SARS-CoV-2 for whom illness duration could be determined,  
90 considered overall and within younger (5-11 years) and older (12-17 years) age groups.  
91 Data from symptomatic children testing negative for SARS-CoV-2, matched 1:1 for age,  
92 gender, and week of testing, were also assessed.

93

### 94 **Findings**

95 1,734 children (588 younger children, 1,146 older children) had a positive SARS-CoV-2 test  
96 result and calculable duration of illness within the study time frame. The commonest  
97 symptoms were headache (62.2%) and fatigue (55.0%). Median illness duration was six  
98 days (vs. three days in children testing negative), and was positively associated with age (rs  
99 0.19,  $p < 1.e-4$ ) with median duration of seven days in older vs. five days in younger children.

100

101 Seventy-seven (4.4%) children had illness duration  $\geq 28$  days (LC28), more commonly  
102 experienced by older vs. younger children (59 (5.1%) vs. 18 (3.1%),  $p = 0.046$ ). The  
103 commonest symptoms experienced by these children were fatigue (84%), headache (80%)  
104 and anosmia (80%); however, by day 28 the median symptom burden was two. Only 25  
105 (1.8%) of 1,379 children experienced symptoms for  $\geq 56$  days. Few children (15 children,  
106 0.9%) in the negatively-tested cohort experienced prolonged symptom duration; however,  
107 these children experienced greater symptom burden (both throughout their illness and at day  
108 28) than children positive for SARS-CoV-2.

109

### 110 **Interpretation**

111 Some children with COVID-19 experience prolonged illness duration. Reassuringly,  
112 symptom burden in these children did not increase with time, and most recovered by day 56.  
113 Some children who tested negative for SARS-CoV-2 also had persistent and burdensome

114 illness. A holistic approach for all children with persistent illness during the pandemic is  
115 required.

116

117

118 **Funding**

119 Engineering and Physical Sciences Research Council (EPSRC), National Institute for Health  
120 Research (NIHR), Medical Research Council (MRC), Zoe Global Limited, The Wellcome  
121 Trust, Alzheimer's Society.

122

## 123 Introduction

124 To date, the COVID-19 pandemic has resulted in >120 million cases of infection and 2.5  
125 million deaths globally,<sup>1</sup> with widespread health, economic, and social chaos. In adults,  
126 severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) causes a  
127 predominantly respiratory illness<sup>2</sup> of median duration 11 days.<sup>3</sup> In contrast, children with  
128 SARS-CoV-2 infection are often asymptomatic (43%-68%<sup>4</sup>) or have relatively mild  
129 symptoms, most commonly cough and fever;<sup>4-9</sup> and life-threatening illness or death is rare.  
130 1,575 children (aged 0-17 years) hospitalised in England from 19 March 2020 to 3 March  
131 2021 tested positive for SARS-CoV-2, noting that COVID-19 was not necessarily the reason  
132 for hospitalisation,<sup>10</sup> and 29 deaths due to COVID-19 were reported in children and young  
133 people across the UK from 1 March 2020 to 29 January 2021 (0-9 years: seven deaths; 10-  
134 19 years: 22 deaths, 0.19% and 1.98% respectively of estimated all-cause deaths during this  
135 time period<sup>11</sup>). The pandemic has also seen emergence of a new rare condition, multisystem  
136 inflammatory syndrome in children (MIS-C), typically presenting 2-4 weeks after acute  
137 SARS-CoV-2 infection.<sup>12</sup>

138  
139 Some adults with SARS-CoV-2 infection experience prolonged duration of illness, known  
140 variably as Long COVID (LC),<sup>3,13</sup> ongoing symptomatic COVID-19, post-COVID-19  
141 syndrome or post-COVID condition.<sup>14,15</sup> Data from the King's College London (KCL) COVID  
142 Symptom Study (CSS),<sup>16</sup> currently the largest citizen participatory epidemiological study in  
143 the UK with over >4.5 million UK participants, showed that 13.3% adults with a positive  
144 SARS-CoV-2 test had symptoms for  $\geq 4$  weeks (LC28) and 4.5% for  $\geq 8$  weeks (LC56).<sup>3</sup>  
145 Predictors of LC28 included older age, female gender, and higher symptom burden in the  
146 first week of illness.<sup>3</sup> Whether some children may also experience prolonged illness duration  
147 after infection with SARS-CoV-2<sup>15</sup> and, if so, how this compares with illness after infection  
148 with other respiratory viruses, is currently unclear.

149  
150 In September 2020, coinciding with full re-opening of primary and secondary schools in the  
151 UK, governance for CSS data usage was extended to allow analysis of data from children  
152 (i.e., individuals aged <18 years). The UK subsequently experienced further waves of the  
153 pandemic (up to 30,000 new cases per day in November 2020 and 60,000 new cases per  
154 day in January 2021),<sup>1,17</sup> with 29 December 2020 the peak date for new specimens testing  
155 positive over the entire pandemic to date.<sup>17</sup> During this time, there was widespread testing  
156 availability for individuals with key symptoms of fever, cough and anosmia, in contrast to the

157 very limited access during the first wave, when testing was mostly restricted to individuals  
158 presenting to hospital.<sup>18,19</sup>

159

160 Stay-at-home directives and school closures during these later waves resulted in unusually  
161 low incidences of commonly circulating viruses such as influenza, adenovirus, and  
162 respiratory syncytial virus over the 2020-21 UK winter, both generally and in school-aged  
163 children specifically.<sup>20</sup> However, overlap in symptomatology meant many individuals (both  
164 adults and children) with respiratory illnesses other than COVID-19 were tested for SARS-  
165 CoV-2.

166

167 Here we report overall illness duration, individual symptom prevalence and duration, and  
168 symptom burden in UK school-aged children testing positive for SARS-CoV-2, whose data  
169 were logged through the KCL CSS. We provide similar data for symptomatic children tested  
170 for SARS-CoV-2 but who were negative, during the same period. Lastly, we present the  
171 prevalence and characteristics of long COVID in children.

172

## 173 **Methods**

174 Data were acquired within the COVID Symptom Study (CSS), through a mobile application  
175 launched jointly by Zoe Global Ltd. and KCL on 24 March 2020.<sup>16</sup> Briefly, individuals are  
176 prompted to report through a smartphone application and provide daily updates of their  
177 health status, symptomatology, any SARS-CoV-2 testing, vaccination, and health care  
178 access. Symptom assessment includes both direct questions for a list of symptoms (yes/no  
179 or other defined options, listed in Supplementary Table 1), and free-text entry.<sup>16</sup> Adult  
180 contributors can also report as a proxy for other persons (children, spouses, elderly relatives,  
181 etc.). The relationship between the contributor and proxy-reported individual(s) is not  
182 solicited and there is no data linkage between the contributor and proxy-reported  
183 individual(s). Children aged 16-17 years can use the app directly as independent  
184 contributors or be proxy-reported by an adult.

185

186 UK data from school-aged children (aged 5-17 years) were available from the launch of the  
187 app to 22 February 2021, which latter date corresponds to eight weeks after the peak SARS-  
188 CoV-2 positive specimen date in the UK.<sup>17</sup> Data were considered from launch of the app,  
189 and from 1 September 2020 (i.e., return-to-school). The cohort was analysed overall and  
190 within two age groups: younger children, aged 5-11 years, corresponding to primary school-  
191 aged children in the UK; and older children, aged 12-17 years, corresponding to secondary

192 school-aged children in the UK (acknowledging that not all older teenagers attend school).  
193 Preschool-aged children ( $\leq 4$  years) were not included in the current study.

194

195 Aligning with our previous publications in adults,<sup>3,16</sup> children were considered symptomatic of  
196 COVID-19 if they were reported by proxy as having any of a specific list of symptoms  
197 associated with COVID-19<sup>16</sup> (Supplementary Table 1), mainly informed by adult  
198 epidemiology,<sup>21</sup> with first symptom(s) presenting within a timeframe of 1 week before and 2  
199 weeks after confirmation of infection (either a SARS-CoV-2 polymerase chain reaction or a  
200 lateral flow test). Illness duration was calculated as time from first symptom(s) reported  
201 within the requisite time frame (having been previously asymptomatic) until time of recovery  
202 (defined as return to asymptomatic state or, if proxy-reporting ceased prior to logging of an  
203 asymptomatic report, time of final report). Individuals who had returned to asymptomatic  
204 state but for whom another symptomatic report was logged within one week of the last  
205 symptomatic report were considered as still being unwell from their initial presentation (i.e.,  
206 allowing for waxing/waning of illness); calculation of illness duration incorporated these short  
207 periods of asymptomatic status. Individuals with reporting gaps longer than one week  
208 between symptomatic reports were excluded. Individual symptom prevalence and duration  
209 were assessed, with individual symptom duration calculated as time between the first and  
210 last report for that symptom. Symptom burden was calculated as the number of different  
211 symptoms reported at least once over a defined timeframe (during the first week, the first 28  
212 days, at  $\geq 28$  days until end of illness, and over the entire duration of illness). Consistent with  
213 our previous study in adults,<sup>3</sup> we termed illness with symptoms lasting longer than 28 days  
214 as LC28; and longer than 56 days, LC56. Thus, by virtue of data census dates LC28 could  
215 only be determined in proxy-reported children whose symptoms commenced on or before 24  
216 January 2021, and for LC56 on or before 29 Dec 2020 (noting the peak positive specimen  
217 date in the UK was 29 December 2020<sup>17</sup>).

218

219 Symptom profiles were also assessed in children with COVID-19 who presented for hospital-  
220 based care (presenting to the accident and emergency department or admitted to hospital),  
221 where presentation to hospital followed development of symptoms (i.e., when the positive  
222 SARS-CoV-2 test result was not a secondary finding in a hospitalised child).

223

224 Several additional direct symptom questions were added to the app on 4 November 2020  
225 (Supplementary Table 2), some of which overlapped with existing questions (e.g., for  
226 cutaneous manifestations, questions on “rash” and “sensitive skin” were added to existing  
227 questions on “red welts”, “blisters”, and “sores”). These additional questions and resultant



228 data are presented in Supplementary Table 2 and Supplementary Figure 1 respectively but  
229 were not included in illness duration or symptom burden calculations for the main analysis.

230

231 Free text reporting was also possible, across the entire period. Free text data were divided  
232 into themes using frequency of descriptive words; each item within the themes were  
233 subsequently independently scrutinised by two clinicians (MA, ELD) to ensure appropriate  
234 categorisation, and individuals reporting free text symptoms within those themes were then  
235 counted. Free text data are reported here as descriptive statistics (Supplementary Table 3)  
236 and were not included in calculating illness duration or symptom burden. Free text was also  
237 searched for specific neurological terms of interest (e.g., weakness, difficulties with balance,  
238 paralysis, seizures, fits, convulsions, paroxysms, tics) and symptoms potentially affecting  
239 attention, behaviour, learning, and school performance (e.g., anxiety, irritability).<sup>22</sup> Symptoms  
240 already assessed by direct question (Supplementary Table 1) were excluded from the free  
241 text search, to avoid duplication.

242

243 Symptom profile and duration were also assessed in children who were tested but had a  
244 negative result for SARS-CoV-2. The same parameters regarding test timing relative to  
245 symptom onset were applied as for children with a positive test result. Illness duration and  
246 symptom profile were determined in a randomly selected control cohort of these children  
247 (matched 1:1 for age, gender, and week of testing), and compared to children with a positive  
248 test.

249

250 Proxy-reporting density (defined as the number of episodes of proxy-reporting over the  
251 duration of illness) and persistence (defined as proxy-reporting until return to healthy state)  
252 were also determined.

253

254 Prevalence data for common winter circulating viruses were obtained from the Public Health  
255 England weekly national influenza and COVID-19 surveillance report.<sup>20</sup>

256

257 Data are presented using descriptive statistics. Results are presented as median with  
258 interquartile ranges. Due to rarity (with most percentages less than 5%) confidence intervals  
259 were calculated using Poisson distribution. Comparisons of data between groups used  
260 Wilcoxon signed-rank test or Chi-squared test/Fisher's exact test, as appropriate. Spearman  
261 correlation testing (which does not require Gaussian distribution of the data) was used to  
262 assess correlation of illness duration with age.

263

264 Ethics approval for this study was granted by the KCL Ethics Committee REMAS ID 18210,  
265 review reference LRS-19/20-18210 and all participants (here, the proxy-reporting adult)  
266 provided consent.

267

## 268 **Results**

269 Across the UK, 258,790 children aged 5-17 years were reported by proxy between 24 March  
270 2020 and 22 February 2021, with a positive SARS-CoV-2 test result reported in 6,975  
271 children. Among those, 1,912 (666 younger and 1,246 older) children had a calculable  
272 duration of illness with requisite logging frequency (at least once weekly). As only 36 children  
273 had illness onset prior to 1<sup>st</sup> September 2020, and as there was very limited community  
274 access to testing early in the UK pandemic experience,<sup>19</sup> analyses of illness duration and  
275 symptom profiles were restricted to children with illness onset after 1 September 2020.  
276 Further, illness onset had to commence on or before 24 January 2021 to allow sufficient time  
277 for symptom duration  $\geq 4$  weeks to be evident, as per LC28 definition.<sup>3</sup> Thus, overall, 1,734  
278 children (588 younger children, 1,146 older children) had a calculable illness duration within  
279 the requisite time frame. Similarly, 1,379 individuals (445 younger; 934 older children) had  
280 symptoms commencing on or before 29 December 2020, allowing sufficient time for  
281 symptom duration  $\geq 8$  weeks to be evident, as per LC56 definition.<sup>3</sup> A flow chart showing  
282 inclusion/exclusion steps is shown in Figure 1.

283

284 Among 16- and 17-year-old individuals, 29,047 contributed self-logged data (447 reporting  
285 testing positive) compared to 32,271 reported by proxy (1,197 reported as testing positive).  
286 Illness duration could only be calculated in 10 self-logged 16- and 17-year-olds, compared  
287 with 381 proxy-logged 16- and 17-year-olds; and self-reporting and proxy-reporting of the  
288 same young person could not be excluded. Thus, only proxy-reported data are presented  
289 here.

290

### 291 ***Illness in children who tested positive for SARS-CoV-2.***

292

293 The median illness duration in children with COVID-19 was six days [IQR 3;11] (Table 1).  
294 Illness duration was significantly shorter in younger compared with older children (five [IQR  
295 2;9] vs. seven days [IQR 3;12]) (Mann-Whitney U test  $p < 1.e-5$ ); and age correlated strongly  
296 with illness duration ( $r_s$  0.19,  $p < 1.e-4$ ).

297

298 Individual symptom prevalence and duration are shown in Table 2, Figure 2 and Figure 3.  
299 Overall, the most reported symptoms were headache (62.2% overall: 55.1% younger  
300 children, 65.9% older children) and fatigue (55.0% overall: 43.9% younger children and  
301 60.7% older children). Subsequent symptoms ranked by frequency were fever (43.7%), sore  
302 throat (36.2%), abdominal pain (27.7%), and persistent cough (24.7%) in younger children;  
303 and in older children sore throat (51.0%), anosmia (48.3%), fever (34.6%), and persistent  
304 cough (26.0%). During the first week of illness, median symptom burden was three [IQR 2;6]  
305 overall (three [IQR 2;5] symptoms in younger children, four [IQR 2;6] in older children).  
306 Sixteen younger children and 21 older children who tested positive for SARS-CoV-2  
307 subsequently attended for hospital care. The symptom profiles of children attending hospital  
308 compared with children managed in the community are shown in Supplementary Figure 2.  
309 No formal statistical comparisons were undertaken between hospital and community cases,  
310 given the low numbers of hospital attendees.

311

### 312 ***Long illness duration in children who tested positive for SARS-CoV-2.***

313

314 Overall, 77 (4.4% [95% CI 3.5-5.5]) of 1,734 children (18 younger children, 59 older children)  
315 had symptoms for  $\geq 28$  days, meeting the definition of LC28. The median symptom burden in  
316 these children was six symptoms [IQR 4;8] reported at least once during the first week of  
317 illness, and eight symptoms [IQR 6;9] reported at least once over the duration of their illness.  
318 However, by day 28 median symptom burden was low, at two [IQR 1;4] (younger children:  
319 three [IQR 1;4]; in older children, one [IQR 1;3]). The commonest symptoms experienced by  
320 children with LC28 over the duration of their illness were fatigue (experienced by 84.4% of  
321 children), headache (77.9%), anosmia (77.9%) and sore throat (74.0%). Figure 4 is a heat  
322 map of symptom profile and progression over the first 28 days in children with LC28.

323

324 Twenty-five (1.8% [95% CI 1.2-2.7]) of 1,379 children had symptoms for  $\geq 56$  days, meeting  
325 the definition of LC56.<sup>3</sup> The median burden of symptoms in these children was six [IQR 4;8]  
326 symptoms reported at least once during the first week, and eight [IQR 6;10] symptoms  
327 reported at least once over the duration of their illness. The commonest symptoms  
328 experienced by children with LC56 over the duration of their illness were anosmia (84.0%),  
329 headache (80.0%), sore throat (80.0%) and fatigue (76.0%).

330

331 Consistent with correlation of illness duration with age across the cohort overall, older  
332 children were more likely to manifest symptoms  $\geq 28$  days, compared with younger children  
333 (59 (5.1%) of 1146 older children vs. 18 (3.1%) of 588 younger children, Chi-squared two-tail  
334 test  $p=0.046$ ). However, this difference was no longer significant in the smaller number of

335 children with illness duration  $\geq$  56 days (6 (1.3%) of 445 younger children vs. 19 (2.0%) of  
336 934 older children, Fisher's exact test  $p=0.52$ ).

337

### 338 ***Symptom Reporting from Additional Questions (added 4 November 2020) and Free*** 339 ***Text Analysis***

340

341 Considering the additional questions added to the CSS app on 4 November 2020,  
342 rhinorrhoea was the most reported symptom (45.8% younger children; 53.5% older children)  
343 followed by sneezing (36.3% younger children; 36.6% older children) (Supplementary Figure  
344 1), with similar prevalence when considered over the entire illness duration in children with  
345 LC28 overall (51.4% rhinorrhoea, 48.9% sneezing).

346

### 347 ***Potential neurological symptoms***

348

349 As mentioned, headache and fatigue were the commonest symptoms in children testing  
350 positive for SARS-CoV-2, overall and in each age group. Dizziness (without differentiation  
351 between light-headedness and vertigo) was reported in 84 (14.3%) younger and 300  
352 (26.2%) older children, with median duration of two [IQR 1;4] and two [IQR 1;5] days  
353 respectively. Symptoms consistent with confusion (encompassing confusion, disorientation,  
354 and drowsiness) were reported in 15 (2.6%) younger and 81 (7.1%) older children (median  
355 duration 2 day [IQR 1;2] and one day [IQR 1;3] respectively). No formal statistical  
356 comparisons of these symptoms in children with shorter or longer illness duration were made  
357 given the low prevalence of these symptoms in children with LC28 (Figure 4).

358

359 With respect to questions added to the app on 4 November 2020 (Supplementary Table 2),  
360 and with the sample size reduced because of the reduced timeframe, 'brain fog' was  
361 reported for 44 (8.7%) of 507 younger children (median duration one day [IQR 1;4]) and 188  
362 (20.2%) of 932 older children (median duration two days [IQR 1;5]); and low mood was  
363 reported for 40 (8.0%) younger children (median duration two days [IQR 1;3.5]), and 145  
364 (15.6%) older children (median duration two days [IQR 1;4.25]) (Supplementary Figure 1).

365

366 Free text searching for specific neurologic symptoms disclosed very few reports of weakness  
367 (two children) or tics (one child). No severe neurological manifestations (paralysis, ataxia,  
368 epileptic seizures, fits, convulsions, paroxysms) were reported (Supplementary Table 3).  
369 Irritability (three children), emotional difficulties (two children), and behavioural difficulties  
370 (one child) were reported rarely; impaired attention, impaired concentration, and anxiety  
371 were not reported.

372

373 ***Illness in symptomatic children who tested negative for SARS-CoV-2.***

374

375 15,597 symptomatic children (8,761 younger children, 6,836 older children), tested for  
376 SARS-CoV-2 infection but with a negative result, with logging at least once weekly and with  
377 calculable illness duration within the requisite time frame, were proxy-reported.

378 Demographic details of the randomly selected matched control sample are shown in Table 1.

379

380 The median illness duration in these children was three days [IQR 2;7] (younger children  
381 three days [IQR 2;7]; older children four days [IQR 2;7]), significantly shorter than for  
382 children with a positive SARS-CoV-2 test (Wilcoxon signed rank test  $p < 1.e-5$ ). The individual  
383 symptom profile is shown in Supplementary Figure 4. The most frequently reported  
384 symptoms over the entire illness duration were sore throat (46.6%), headache (38.8%), fever  
385 (30.4%), fatigue (26.9%), and abdominal pain (24.7%) in younger children; and sore throat  
386 (60.6%), headache (48.8%), fatigue (37.2%), fever (20.4%) and persistent cough (20.6%) in  
387 older children.

388

389 ***Long illness duration in children who tested negative for SARS-CoV-2.***

390

391 Few children with a negative test for SARS-CoV-2 had illness duration for  $\geq 28$  days (15 of  
392 1,734 children; 0.9%; 95% CI [0.5-1.4]). This was significantly fewer than children with a  
393 positive test, considered overall (Chi-squared 2-tail test  $p < 1.e-10$ ) and by age group (in  
394 younger children, three (0.5%) vs. 18 (3.1%); Fisher's exact test:  $p = 0.001$ ; in older children,  
395 12 (1.1%) vs. 59 (5.1%); Fisher's exact test:  $p < 1.e-8$ ). The symptom profile of these children  
396 over the first 28 days is shown in Supplementary Figure 4. However, older children with a  
397 negative test for SARS-CoV-2 whose illness duration was  $\geq 28$  days had a greater symptom  
398 burden than was experienced by children with LC28, both at  $\geq 28$  days (Supplementary  
399 Figure 5), and over their entire illness duration (Supplementary Figure 6) ( $p = 0.005$  and  
400  $p = 0.025$  respectively, Mann-Whitney-U tests).

401

402 ***Proxy-reporting density***

403

404 Overall, proxy-reporting density (number of logging episodes/illness duration in days) was  
405 assiduous for all children. Reporting density was significantly higher in children with a  
406 negative test for SARS-CoV-2, compared to children with a positive test (reporting density in  
407 children negative vs positive: in younger children: 1 [IQR 0.68;1] vs. 0.89 [IQR 0.6;1]; and in

408 older children 1 [IQR 0.67;1] vs. 0.8 [IQR 0.57;1]), noting the shorter illness duration in  
409 children with a negative test.

410

### 411 ***Proxy-reporting perseverance***

412

413 Children were included in this study if their illness onset corresponded temporally to testing  
414 for SARS-CoV-2, and either a healthy report was received (1,551 (89.4%) of children with a  
415 positive test and 1,674 (96.5%) of children with a negative test) or proxy-reporting ceased.

416

417 Amongst children with a positive SARS-CoV-2 test, logging ceased in 183 children prior to a  
418 healthy report (22 children with LC28, 161 with [assumed] shorter illness duration). In  
419 children with LC28, a healthy report was received in 71.4% [55/77]. However, the remaining  
420 22 children had already had symptoms logged for more than 28 days and thus fulfil the  
421 definition of LC28. In children with [assumed] shorter illness duration, a healthy report was  
422 received for 90.3% [1496/1657]. For the remaining 161 children, median symptom burden at  
423 last report was two [IQR 1;3]; and proxy-reporting usually ceased early in illness (logging  
424 cessation rates: 11.3% of children with illness duration <10 days; 5.5% ≥10 days). Thus, for  
425 children for whom proxy-reporting ceased prior to logging of a healthy report, we have  
426 assumed that proxy-reporting cessation coincided with illness resolution (i.e., that adults  
427 stopped proxy-reporting because the child had recovered) and illness duration was  
428 calculated assuming last day of logging corresponded to last day of illness.

429

430 We considered the impact of this assumption. Excluding all children with a positive SARS-  
431 CoV-2 test for whom a healthy report was not logged, median duration of illness in the  
432 remaining 1,551 was unchanged (6 days [IQR 3;11]) with prevalence of LC28 3.5%  
433 [55/1551], within the confidence intervals for LC28 using data from the entire cohort.

434 Excluding only the 161 children with [assumed] short symptoms but including all children  
435 who had fulfilled the definition of LC28 (regardless of receipt of healthy report), prevalence of  
436 LC28 was 4.9% (77/1,573 children), again within the confidence intervals for LC28 using the  
437 entire cohort.

438

439 In children with a negative SARS-CoV-2 test, logging ceased in 60 children prior to a healthy  
440 report (four of 15 children with long illness duration, 56 of 1,719 children with [assumed]  
441 short illness duration). Proxy-reporting until logging of a healthy report was higher in children  
442 with a negative test, compared with children with a positive test (Chi-squared 2-tail test  
443  $p < 1.e-15$ ).

444



445 Data governance did not allow assessment of familial relationships between proxy-reported  
446 individuals and the contributor; thus, we cannot comment whether concurrent illness of the  
447 contributor or other family members affected proxy-reporting.

448

## 449 **Discussion**

450 In this large study of UK school-aged children recruited via the CSS study app, we have  
451 shown that symptomatic infection with SARS-CoV-2 in children is usually short, with a  
452 median duration of illness of six days compared to 11 days in adults,<sup>3</sup> and with low symptom  
453 burden (Figure 3). Prolonged illness duration can occur but is infrequent (4.4% with  
454 symptoms  $\geq 28$  days; 1.8% with symptoms  $\geq 56$  days), considerably lower than observed in  
455 adults using the same disease definitions (prevalence in adults of LC28: 13.3% and of LC56:  
456 4.5%).<sup>3</sup> Age is a risk factor for longer symptom duration (both overall, and specifically for  
457 illness duration  $\geq 28$  days), consistent with our previous findings in adults.<sup>3</sup>

458

459 Similar to adults,<sup>3</sup> the commonest symptoms in children with COVID-19 were headache  
460 (62.2%) and fatigue (55.0%) (Table 2, Figure 2). A previous meta-analysis of studies in  
461 children with COVID-19, which included community-based and hospitalized children,  
462 identified fever (47%) and cough (42%) as the commonest symptoms.<sup>23</sup> However, headache  
463 and fatigue were only assessed in half of contributing studies. In our (almost entirely  
464 community-managed) cohort, prevalence of fever was 37.7%, and persistent cough 25.5%.  
465 Anosmia (here, both anosmia and dysosmia) was also common in our cohort (39.6% overall:  
466 22.4% of younger children, 48.3% of older children). Certainly, for older children this  
467 symptom was reported more often than was observed in a previous small study of  
468 adolescents (aged 10-19 years) with 'mild to moderate' COVID-19, ascertained from a single  
469 centre, in whom prevalence of anosmia was 24.1%,<sup>24</sup> noting that anosmia was one of the  
470 core symptoms determining access to testing in the UK during our study period.

471

472 In children with symptoms  $\geq 28$  days, symptom burden was low by day 28 (median symptom  
473 burden of two). However, fatigue was a symptom at some stage in almost all (84.4%) of  
474 these children (Figure 4, Supplementary Figure 6). In adults, fatigue has been reported in  
475 many studies as the commonest symptom of long COVID, although prevalence varies. In our  
476 previous study in adults,<sup>3</sup> fatigue was almost universal in LC28 (97.7% of cases experienced  
477 fatigue during their illness). Other studies have also reported persistence of fatigue after  
478 acute infection in adults (e.g., 53.1% at 60 days<sup>25</sup>; and 52.3% at 10 weeks<sup>26</sup>).

479

480 Considering the prevalence and persistence of headache and fatigue within the context of  
481 usual prevalence of these symptoms within the general paediatric population is difficult, as  
482 few large-scale epidemiological studies have been undertaken in children to provide  
483 normative population data. Considering headache, a systematic review of headache  
484 comprising 38 unselected population-based studies in individuals under 20 years reported  
485 that around 60% of children are “prone to headache”.<sup>27</sup> A random sample of 2,165 school  
486 children from Aberdeen aged 5-15 years found that 1,166 (66%) had headaches over the  
487 previous year, which in 391 (22%) children were of sufficient severity to stop normal  
488 activities.<sup>28</sup> Considering fatigue, a study of 2,936 children found that 129 (4.4%) had “more  
489 than a few days of disabling fatigue”.<sup>29</sup> Prevalence of chronic fatigue syndrome (defined here  
490 as “disabling fatigue lasting >3 months with one additional symptom, where no other cause  
491 for the fatigue could be established”) was 1% in a study of 11-16-year-old children from three  
492 secondary schools in England.<sup>30</sup> Prevalence of “chronic disabling fatigue” reported by the  
493 Avon Longitudinal Study of Parents and Children (defined here as fatigue lasting >6 months  
494 associated with absence from full-time school or that had prevented the child from taking  
495 part in activities ‘quite a lot’ or ‘a great deal’, and not due to excess of physical activity) was  
496 1.5% and 2.2% at 13- and 16- years respectively.<sup>31</sup> Considering fatigue after viral infection  
497 specifically, and choosing one of the younger published cohorts, median symptom duration  
498 with Epstein–Barr virus in symptomatic university students (i.e., older than the cohort  
499 reported in our study) was 10 days (mean 17, range 3-66 days), with fatigue persisting for a  
500 median of 15.5 days.<sup>32</sup> These studies indicate the wide range of prevalence of these  
501 symptoms in paediatric populations generally.

502

503 The paucity of contemporaneous data comparing illness duration and symptom profiles from  
504 different viruses also complicates contextualisation of illness due to SARS-CoV-2 infection in  
505 children. A preprint paper comparing data from 55,270 children/adolescents with COVID-19  
506 (3,693 of whom were hospitalized) with a non-contemporaneous cohort of 1,952,693  
507 children with influenza during 2017-19 (hospitalised numbers unclear) suggests that  
508 dyspnoea, anosmia, and gastrointestinal tract symptoms are more common in children with  
509 COVID-19 than in children with influenza.<sup>33</sup> However, symptoms and overall illness duration  
510 were only reported as present or absent at 30 days in both groups, preventing more granular  
511 comparisons.

512

513 Here, a strength of our study was our ability to compare contemporaneous illness profiles of  
514 symptomatic children testing positive vs. negative for SARS-CoV-2, matched for age,  
515 gender, and week of testing. Children testing positive for SARS-CoV-2 had longer median  
516 illness duration (six days vs. three days in negatives); and were more likely to have illness



517 duration  $\geq 28$  days (4.4% vs. 0.9%). However, some children testing negative for SARS-CoV-  
518 2 also had symptoms that lasted  $>28$  days, and these children had a higher symptom count  
519 both over the duration of their illness and at day 28 (Supplementary Figures 4, 5),  
520 acknowledging here that our sample size is small. We considered whether some children  
521 with long illness duration who tested negative for SARS-CoV-2 might have false negative  
522 results. However, there is no evidence that sensitivity and specificity of testing for SARS-  
523 CoV-2 are different in adults compared with children, with sensitivity for PCR SARS-CoV-2  
524 tests around 95%.<sup>34</sup>

525

526 Additionally, the symptom profiles of children negative for SARS-CoV-2 (Supplementary  
527 Figures 4, 5, 6) suggest some differences in their illness compared with children with positive  
528 results. Relevantly, the prevalence of non-SARS-CoV-2 respiratory viruses (influenza A,  
529 influenza B, parainfluenza, adenovirus, rhinovirus, and respiratory syncytial virus) was  
530 unusually and extremely low over the UK winter of 2020/2021<sup>35-37</sup>, with the exception of the  
531 commonly observed rhinovirus peak coinciding with the September return-to-school.<sup>20</sup> With  
532 relaxation of personal protection and social distancing measures, it is likely that these  
533 illnesses will return to more usual (i.e., higher) levels of circulation in future UK winters. Our  
534 data highlight that other illnesses may also have a protracted and burdensome course in  
535 children, which will also need consideration in post-pandemic service delivery planning.

536

537 Short and long-term effects of COVID-19 on school performance and learning have been a  
538 recent matter of concern.<sup>38</sup> In our cohort, neither attentional problems nor memory  
539 complaints nor anxiety were reported. Isolated cases of low mood and/or irritability were  
540 consistent with, if not lower than, previously reported statistics in the general school-aged  
541 healthy population.<sup>39</sup> Our data do not support anecdotal reports of weakness and seizures  
542 as common features in children with COVID-19, whether of short or longer illness duration;  
543 and no severe neurological symptoms were reported. However, persistence of symptoms  
544 from any illness can be associated with low mood, with adverse long-term outcomes  
545 including school refusal and separation anxiety.<sup>40</sup> Although self-reporting adults were able to  
546 participate in specific questions regarding mental health, these data could not be proxy-  
547 reported. This limits our ability to assess mental health issues comprehensively, and any  
548 potential impact on school performance and learning, in children during the COVID-19  
549 pandemic whether testing positive or negative for SARS-CoV-2.

550

551 In considering how our data relates to other sources, the UK Office for National Statistics  
552 (ONS) conducted a round of testing for SARS-CoV-2 (irrespective of symptoms) from 2 to 10  
553 December 2020, prior to the UK peak of infection, with deliberate oversampling of schools

554 which had had the highest infection rates at the start of the academic year. 121 schools (41  
555 primary, 80 secondary) in 15 local authorities were examined, with a total of 7,089 pupils.<sup>41</sup>  
556 Primary school pupils and staff had a slightly lower percentage testing positive (0.94% and  
557 0.99% respectively) for SARS-CoV-2 than secondary pupils and staff (1.22% and 1.64%).  
558 ONS warned that their conclusions might not have general validity; and these figures do not  
559 capture time fluctuations as the pandemic progressed. In our dataset, with data captured  
560 until 22 February 2021 (thus including the subsequent rise in numbers over Christmas and  
561 New Year), 6,043 of 258,790 (2.3%) of proxy-reported children were reported with a positive  
562 test (2.3% of younger children, 3.7% of older children), noting that reporting was voluntary,  
563 by proxy, and through a specific COVID-19 platform, and that testing was only available for  
564 symptomatic individuals. Additionally, the CSS app user base (considered as a whole) is not  
565 fully representative of the wider UK population, due to over-representation of female gender,  
566 white background, and above-average socioeconomic status.<sup>18</sup> Further, we cannot  
567 characterise regional variability, as geographic information was not available for many  
568 participants.

569  
570 We considered what proportion of the total number of school-aged children in the UK testing  
571 positive for SARS-CoV-2 were proxy-reported to the CSS. The different countries of the UK  
572 report data for children within different age groups and over varying time periods. In England  
573 there were 390,866 positive tests in young people aged 5-19 years from 1 September 2020  
574 to 24 January 2021 (5-9 years: 69,641 children; 10-19 years: 321,225 individuals).<sup>20</sup> In  
575 Scotland, 15,869 children aged 0-14 years, and 14,597 young people aged 15-19 years have  
576 tested positive from the start of the pandemic to 30 March 2021.<sup>42</sup> In Wales there were  
577 ~28,300 cases in children and young people from the start of the pandemic to 30 March  
578 2021.<sup>43</sup> In Northern Ireland 13,268 individuals aged 0-19 years from the start of the  
579 pandemic to 30 March 2021.<sup>44</sup> Thus, our study represents ~1-2% of all school-aged children  
580 with positive tests across the UK during this time, noting that many of these national figures  
581 include young adults and preschool-aged children.

582  
583 The ONS has also provided estimates of long COVID in children aged 2-16 years, with the  
584 most recent data release (April 2021) suggesting that 9.8% of children aged 2-11 years and  
585 13.0% of those aged 12-16 years experience ongoing symptoms five weeks after testing  
586 positive for SARS-CoV-2, and 7.4% and 8.2% respectively are still reporting symptoms at 12  
587 weeks.<sup>45</sup> These latest figures include a control group (defined as those who were never  
588 symptomatic, never tested, never-self isolated, and never a contact of anyone testing  
589 positive for SARS-CoV-2) which suggested 'baseline' rates for the same symptoms of 2%  
590 amongst 2- to 11-year-olds and 1.7% amongst 12- to 16-year-olds. Earlier, in January 2021,

591 ONS had reported long COVID symptoms by age; however, updated age-specific estimates  
592 for specific symptoms were not included in April 2021 data release. Overall ONS long  
593 COVID prevalence estimates were adjusted downwards between January and April 2021  
594 (e.g., from 12.9% to 9.8% in 2- to 11-year-olds).<sup>45,46</sup>

595

596 There is some disparity between our prevalence data for LC28 in children and those of the  
597 ONS. At least part of the reason may be that the ONS required two consecutive  
598 asymptomatic visits to define the end of illness. Thus, individuals with relapsing/remitting  
599 symptoms in whom asymptomatic periods lasted longer than one week would be captured  
600 by ONS but not by our study. Consistent with this, the ONS' sensitivity analysis of the impact  
601 of defining symptom discontinuity to a single asymptomatic visit radically lowered their  
602 prevalence estimates, especially for ongoing symptoms at 12 weeks, with estimates falling  
603 from 13.7% to 0.9% (ref<sup>47</sup> - Table 11), much more in keeping with our results. Additionally,  
604 ONS estimates are based on both current and recalled data, collected in the first week of  
605 each month. In contrast, our app-based data collection was conducted in real time, with high  
606 density and persistence of proxy-reporting of children (whether the child had tested positive  
607 or negative for SARS-CoV-2). A recent Australian study reported 151 (of an initial cohort of  
608 171) young children (median age three years [IQR 1;8]) who tested positive for SARS-CoV-2  
609 and were followed for three to six months. Twelve (8%) children (median age two years)  
610 were reported to have symptoms 3-8 weeks after initial presentation (most commonly cough  
611 and/or fatigue), all of whom resolved by the end of the study to their baseline health.<sup>23</sup> This  
612 small study concords more closely with our results. None-the-less, and with the methodology  
613 for the ONS experimental estimates not yet published, the ONS estimates have been used  
614 in many service provisions and government discussions, and reported widely in social and  
615 other media.<sup>48,49</sup>

616

617 Our study is part of one of the largest citizen science initiatives ever in the UK, with  
618 generation of real-time epidemiological data from over 4.5 million users across the UK. We  
619 leveraged previously published methodologies assessing illness duration and symptom  
620 profiling in adults, including assessment of long COVID.<sup>3</sup> Our data census points allowed us  
621 to capture all children with illness duration  $\geq 8$  weeks, if they had presented before the date of  
622 peak specimen receipt in the UK; and our restriction to individuals whose symptom  
623 presentation concorded with test timing allowed an accurate determination of symptom  
624 onset. Moreover, by restricting analyses to start from 1 September, we avoided bias due to  
625 limited test availability during the first wave of the pandemic. However, despite general  
626 availability there were still some blocks to testing - in particular, that individuals were  
627 required at least one of a defined list of symptoms (specifically, fever, cough and anosmia),<sup>50</sup>

628 which list was largely informed by adult symptomatology and might not be sufficiently broad  
629 to capture some common paediatric manifestations of COVID-19, (e.g., abdominal pain,  
630 reported in 4% of paediatric cases<sup>4</sup> and in 27.8% of our younger children). Related to this,  
631 the set of questions asked through the app, although refined between 24 March and 1  
632 September, and again on 4 November 2020, was largely informed by research in adults.  
633 Although we cannot exclude the possibility that a paediatric version might capture other  
634 manifestations of COVID-19, the free text data did not suggest common themes emerging  
635 unique to paediatric populations. We did not undertake a formal qualitative analysis of the  
636 free-text data given (a) its *ad hoc* collection rather than a formal qualitative study, and (b) the  
637 potential bias arising from introduction of additional direct symptom questions from 4  
638 November 2020 (i.e., once a symptom was asked about directly, it was unlikely that to be  
639 reported as free text). None-the-less, we have provided the data from free text responses,  
640 and from questions asked after 4 November 2020 in the Supplementary Material. We  
641 acknowledge that symptoms were reported by proxy rather than directly ascertained;  
642 however, this is common in clinical assessment of children, particularly younger children.  
643 Additionally, children cannot directly consent to research participation. We also acknowledge  
644 the possibility that older children may have reported for themselves using their relatives'  
645 phone/log-in function and/or misused proxy-reporting from their own mobile phones;  
646 however, we have no means of capturing such activity.

## 647 **Conclusions**

648 Our national cohort of children and young people provides the first systematic description of  
649 COVID-19 in children. Our data show that long illness duration after SARS-CoV-2 infection  
650 in school-aged children is not common; however, a small proportion of children do have  
651 prolonged illness duration and persistent symptoms, validating these children's experiences.  
652 Our LC56 data provide reassurance regarding the longer term outcome for these children.  
653 The symptom burden in children who tested negative for SARS-CoV-2 but had long illness  
654 duration highlights that allocation of appropriate resources will be necessary for any child  
655 with prolonged illness, whether due to SARS-CoV-2 infection or other illness. Our study  
656 provides timely and critical data to inform discussions around the impact and implications of  
657 the pandemic on UK paediatric healthcare resource allocation.

## 658 **Data sharing**

659 Data collected in the COVID Symptom Study smartphone application are being shared with  
660 other health researchers through the UK National Health Service-funded Health Data  
661 Research UK (HDRUK) and Secure Anonymised Information Linkage consortium, housed in

662 the UK Secure Research Platform (Swansea, UK). Anonymised data are available to be  
663 shared with researchers according to their protocols in the public interest  
664 (<https://web.www.healthdatagateway.org/dataset/fddcb382-3051-4394-8436-b92295f14259>).

## 665 **Acknowledgements**

666 This work is supported by the Wellcome EPSRC Centre for Medical Engineering at King's  
667 College London (WT 203148/Z/16/Z) and the UK Department of Health via the National  
668 Institute for Health Research (NIHR) comprehensive Biomedical Research Centre award to  
669 Guy's & St Thomas' NHS Foundation Trust in partnership with King's College London and  
670 King's College Hospital NHS Foundation Trust. Investigators also received support from the  
671 Medical Research Council (MRC) and British Heart Foundation, the UK Research and  
672 Innovation London Medical Imaging & Artificial Intelligence Centre for Value Based  
673 Healthcare, and the Wellcome Flagship Programme (WT213038/Z/18/Z). EM is funded by  
674 an MRC Skills Development Fellowship Scheme at KCL. CHS is supported by an  
675 Alzheimer's Society Junior Fellowship (AS-JF-17-011). ZOE Global supported all aspects of  
676 building and running the app and service to all users worldwide.

## 677 **Declaration of interests**

678 CH, SS, KR, JCP are employees of Zoe Global Ltd.  
679 All other authors have nothing to declare.

680

681

---

682

## 683 References

684

685

- 686 1 Worldometer. Reported Cases and Deaths by Country or Territory. 2020.  
687 <https://www.worldometers.info/coronavirus/#countries>.
- 688 2 Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and  
689 laboratory findings of the COVID-19 in the current pandemic: Systematic review and  
690 meta-analysis. *BMC Infectious Diseases*. 2020; **20**. DOI:10.1186/s12879-020-05371-  
691 2.
- 692 3 Sudre C, Murray B, Varsavsky T, *et al*. Attributes and predictors of long COVID.  
693 *Nature Medicine* 2021; **Mar 10**. DOI:10.1038/s41591-021-01292-y.
- 694 4 Li B, Zhang S, Zhang R, Chen X, Wang Y, Zhu C. Epidemiological and Clinical  
695 Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis.  
696 *Frontiers in Pediatrics*. 2020; **8**. DOI:10.3389/fped.2020.591132.
- 697 5 Ma N, Li P, Wang X, *et al*. Ocular Manifestations and Clinical Characteristics of  
698 Children with Laboratory-Confirmed COVID-19 in Wuhan, China. *JAMA*  
699 *Ophthalmology* 2020; **138**. DOI:10.1001/jamaophthalmol.2020.3690.
- 700 6 Alsharrah D, Alhaddad F, Alyaseen M, *et al*. Clinical characteristics of pediatric  
701 SARS-CoV-2 infection and coronavirus disease 2019 (COVID-19) in Kuwait. *Journal*  
702 *of Medical Virology* 2020. DOI:10.1002/jmv.26684.
- 703 7 Cai J, Wang X, Zhao J, *et al*. Comparison of Clinical and Epidemiological  
704 Characteristics of Asymptomatic and Symptomatic SARS-CoV-2 Infection in Children.  
705 *Virologica Sinica* 2020; **35**. DOI:10.1007/s12250-020-00312-4.
- 706 8 Chen Z, Tong L, Zhou Y, *et al*. Childhood COVID-19: a multicentre retrospective  
707 study. *Clinical Microbiology and Infection* 2020; **26**. DOI:10.1016/j.cmi.2020.06.015.
- 708 9 Xia W, Guo Y, Tian Z, *et al*. Clinical Features and Temporal Changes of RT-PCR  
709 and Chest CT in COVID-19 Pediatric Patients. *Frontiers in Pediatrics* 2020; **8**.  
710 DOI:10.3389/fped.2020.579512.
- 711 10 Rubens JH, Akindele NP, Tschudy MM, Sick-Samuels AC. Acute covid-19 and  
712 multisystem inflammatory syndrome in children. *The BMJ* 2021; **372**.  
713 DOI:10.1136/bmj.n385.
- 714 11 Evans C, Davies P. SARS-CoV-2 paediatric inflammatory syndrome. *Paediatrics*  
715 *and Child Health (United Kingdom)*. 2021; **31**. DOI:10.1016/j.paed.2020.12.003.
- 716 12 Godfred-Cato S, Bryant B, Leung J, *et al*. COVID-19-Associated Multisystem  
717 Inflammatory Syndrome in Children - United States, March-July 2020. *MMWR Morb*  
718 *Mortal Wkly Rep*; **69**: 1074–80.
- 719 13 Sykes DL, Holdsworth L, Jawad N, Gunasekera P, Morice AH, Crooks MG. Post-  
720 COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?  
721 *Lung* 2021. DOI:10.1007/s00408-021-00423-z.
- 722 14 Nalbandian A, Sehgal K, Gupta A, *et al*. Post-acute COVID-19 syndrome. *Nat Med*  
723 2021. DOI:10.1038/s41591-021-01283-z.
- 724 15 National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline:  
725 managing the long- term effects of COVID-19 (NG188). Evidence reviews 2 and 3:  
726 prevalence. 2020.
- 727 16 Menni C, Valdes AM, Freidin MB, *et al*. Real-time tracking of self-reported symptoms  
728 to predict potential COVID-19. *Nature Medicine* 2020. DOI:10.1038/s41591-020-0916-  
729 2.



- 730 17 Government of the United Kingdom. GOV.UK Coronavirus (COVID-19) in the UK -  
731 Cases by specimen date. 2021.
- 732 18 Varsavsky T, Graham MS, Canas LS, *et al.* Detecting COVID-19 infection hotspots  
733 in England using large-scale self-reported data from a mobile application: a  
734 prospective, observational study. *The Lancet Public Health* 2021; **6**.  
735 DOI:10.1016/S2468-2667(20)30269-3.
- 736 19 Government of the United Kingdom. Coronavirus (COVID-19) in the UK - Lab-based  
737 testing and capacity, by test type. 2021.  
738 <https://coronavirus.data.gov.uk/details/testing>.
- 739 20 Public Health England. Weekly national Influenza and COVID-19 surveillance report  
740 - Week 11 report (up to week 10 data) 18 March 2021. 2021.  
741 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachm  
742 ent\\_data/file/971212/Weekly\\_Flu\\_and\\_COVID-19\\_report\\_w11\\_v2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/971212/Weekly_Flu_and_COVID-19_report_w11_v2.pdf) (accessed April  
743 27, 2021).
- 744 21 Struyf T, Deeks JJ, Dinnes J, *et al.* Signs and symptoms to determine if a patient  
745 presenting in primary care or hospital outpatient settings has COVID-19. Cochrane  
746 Database of Systematic Reviews. 2021; **2021**.  
747 DOI:10.1002/14651858.CD013665.pub2.
- 748 22 O. A-M, M. E, U. L, *et al.* Neurologic and Radiographic Findings Associated with  
749 COVID-19 Infection in Children. *JAMA Neurology* 2020.
- 750 23 Say D, Crawford N, McNab S, Wurzel D, Steer A, Tosif S. Post-acute COVID-19  
751 outcomes in children with mild and asymptomatic disease. *The Lancet Child &*  
752 *Adolescent Health* 2021; published online April. DOI:10.1016/S2352-4642(21)00124-  
753 3.
- 754 24 Kumar L, Kahlon N, Jain A, Kaur J, Singh M, Pandey AK. Loss of smell and taste in  
755 COVID-19 infection in adolescents. *International Journal of Pediatric*  
756 *Otorhinolaryngology* 2021; **142**. DOI:10.1016/j.ijporl.2021.110626.
- 757 25 Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19.  
758 *JAMA - Journal of the American Medical Association*. 2020; **324**.  
759 DOI:10.1001/jama.2020.12603.
- 760 26 Townsend L, Dyer AH, Jones K, *et al.* Persistent fatigue following SARS-CoV-2  
761 infection is common and independent of severity of initial infection. *PLoS ONE* 2020;  
762 **15**. DOI:10.1371/journal.pone.0240784.
- 763 27 Abu-Arafeh I, Razak S, Sivaraman B, Graham C. Prevalence of headache and  
764 migraine in children and adolescents: A systematic review of population-based  
765 studies. *Developmental Medicine and Child Neurology*. 2010; **52**. DOI:10.1111/j.1469-  
766 8749.2010.03793.x.
- 767 28 Abu-Arafeh I, Russell G. Prevalence of headache and migraine in schoolchildren.  
768 *BMJ* 1994; **309**. DOI:10.1136/bmj.309.6957.765.
- 769 29 Farmer A, Fowler T, Scourfield J, Thapar A. Prevalence of chronic disabling fatigue  
770 in children and adolescents. *British Journal of Psychiatry*. 2004; **184**.  
771 DOI:10.1192/bjp.184.6.477.
- 772 30 Crawley EM, Emond AM, Sterne JAC. Unidentified chronic fatigue  
773 syndrome/myalgic encephalomyelitis (CFS/ME) is a major cause of school absence:  
774 Surveillance outcomes from school-based clinics. *BMJ Open* 2011; **1**.  
775 DOI:10.1136/bmjopen-2011-000252.

- 776 31 Norris T, Collin SM, Tilling K, *et al.* Natural course of chronic fatigue  
777 syndrome/myalgic encephalomyelitis in adolescents. *Archives of Disease in*  
778 *Childhood* 2017; **102**. DOI:10.1136/archdischild-2016-311198.
- 779 32 Balfour HH, Odumade OA, Schmeling DO, *et al.* Behavioral, virologic, and  
780 immunologic factors associated with acquisition and severity of primary epstein-barr  
781 virus infection in university students. *Journal of Infectious Diseases* 2013; **207**.  
782 DOI:10.1093/infdis/jis646.
- 783 33 Duarte-Salles T, Vizcaya D, Pistillo A, *et al.* Baseline characteristics, management,  
784 and outcomes of 55,270 children and adolescents diagnosed with COVID-19 and  
785 1,952,693 with influenza in France, Germany, Spain, South Korea and the United  
786 States: An international network cohort study. medRxiv. 2020.  
787 DOI:10.1101/2020.10.29.20222083.
- 788 34 UK Office for National Statistics (ONS), Steel K, Davies B. 5. Test sensitivity and  
789 Specificity. 2021.  
790 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditio](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveyipilotmethodsandfurtherinformation#test-sensitivity-and-specificity)  
791 [nsanddiseases/methodologies/covid19infectionsurveyipilotmethodsandfurtherinformati](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveyipilotmethodsandfurtherinformation#test-sensitivity-and-specificity)  
792 [on#test-sensitivity-and-specificity](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/methodologies/covid19infectionsurveyipilotmethodsandfurtherinformation#test-sensitivity-and-specificity).
- 793 35 National Health Service (NHS). COVID-19 Hospital Activity. 2021.  
794 <https://www.england.nhs.uk/statistics/statistical-work-areas/covid-19-hospital-activity/>.
- 795 36 Public Health Scotland. Weekly national seasonal respiratory report - Week ending  
796 28 March 2021 – week 12. [https://beta.isdscotland.org/media/8300/week-12-](https://beta.isdscotland.org/media/8300/week-12-respiratory-report-full-report-final.pdf)  
797 [respiratory-report-full-report-final.pdf](https://beta.isdscotland.org/media/8300/week-12-respiratory-report-full-report-final.pdf). 2021; published online March 31.
- 798 37 Public Health Wales - National Health Service. Weekly Influenza Activity in Wales  
799 Report. <http://www.wales.nhs.uk/sites3/page.cfm?orgid=457&pid=34338>. 2021;  
800 published online April 7.
- 801 38 Ludvigsson JF. Case report and systematic review suggest that children may  
802 experience similar long-term effects to adults after clinical COVID-19. *Acta*  
803 *Paediatrica, International Journal of Paediatrics* 2021; **110**. DOI:10.1111/apa.15673.
- 804 39 UK Office for National Statistics (ONS) ER. Young people's well-being in the UK:  
805 2020.  
806 [https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/youngpeo](https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/youngpeopleswellbeingintheuk/2020)  
807 [pleswellbeingintheuk/2020](https://www.ons.gov.uk/peoplepopulationandcommunity/wellbeing/bulletins/youngpeopleswellbeingintheuk/2020). 2020; published online Oct 2.
- 808 40 Hysing M, Elgen I, Gillberg C, Lie SA, Lundervold AJ. Chronic physical illness and  
809 mental health in children. Results from a large-scale population study. *Journal of Child*  
810 *Psychology and Psychiatry and Allied Disciplines* 2007; **48**. DOI:10.1111/j.1469-  
811 7610.2007.01755.x.
- 812 41 UK Office for National Statistics (ONS). COVID-19 Schools Infection Survey Round  
813 2, England: December 2020. 2021.  
814 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditio](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround2england/december2020)  
815 [nsanddiseases/bulletins/covid19schoolsinfectionsurveyround2england/december2020](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/covid19schoolsinfectionsurveyround2england/december2020)  
816 .
- 817 42 Public Health Scotland. Total Cases by Age and Sex. 2021.
- 818 43 Public Health Wales TP. Rapid COVID-19 surveillance.  
819 [https://public.tableau.com/profile/public.health.wales.health.protection#!/vizhome/Rapi](https://public.tableau.com/profile/public.health.wales.health.protection#!/vizhome/RapidCOVID-19virology-Public/Headlinesummary)  
820 [dCOVID-19virology-Public/Headlinesummary](https://public.tableau.com/profile/public.health.wales.health.protection#!/vizhome/RapidCOVID-19virology-Public/Headlinesummary). 2021; published online April 16.
- 821 44 Ulster University. Northern Ireland COVID-19 Tracker - Cumulative Number of  
822 Individuals Tested Positive by Age. 2021.  
823 <https://www.ulster.ac.uk/coronavirus/research/impact/ni-covid-19-tracker>.



- 824 45 UK Office for National Statistics (ONS) DA. Prevalence of long COVID symptoms  
825 and COVID-19 complications.  
826 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthand](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications)  
827 [dlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications.](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complications)  
828 2020; published online Dec 16.
- 829 46 UK Office for National Statistics (ONS). Updated estimates of the prevalence of long  
830 COVID symptoms.  
831 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthand](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsymptoms)  
832 [dlifeexpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsympto](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsymptoms)  
833 [ms.](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/adhocs/12788updatedestimatesoftheprevalenceoflongcovidsymptoms) 2021; published online Jan 21.
- 834 47 UK Office for National Statistics (ONS). All data related to Prevalence of ongoing  
835 symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021.  
836 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditio](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021/relateddata)  
837 [nsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19in](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021/relateddata)  
838 [fectionintheuk/1april2021/relateddata.](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021/relateddata) 2021; published online April 1.
- 839 48 Katie Gibbons. Forgotten children living with long Covid,  
840 <https://www.thetimes.co.uk/article/forgotten-children-living-long-covid-s0c6z0f20>. The  
841 Times. 2021; published online March 13.
- 842 49 Scally Gabriel. Why it's not too late for the UK to pursue a zero-Covid strategy.  
843 NewStatesman, [https://www.newstatesman.com/science-](https://www.newstatesman.com/science-tech/coronavirus/2021/02/why-it-s-not-too-late-uk-pursue-zero-covid-strategy)  
844 [tech/coronavirus/2021/02/why-it-s-not-too-late-uk-pursue-zero-covid-strategy.](https://www.newstatesman.com/science-tech/coronavirus/2021/02/why-it-s-not-too-late-uk-pursue-zero-covid-strategy) 2021;  
845 published online Feb 23.
- 846 50 Graham MS, May A, Varsavsky T, *et al.* Knowledge barriers in the symptomatic-  
847 COVID-19 testing programme in the UK: an observational study. *medRxiv* 2021.

848

**Table 1. Characteristics of school-aged children who tested positive for SARS-CoV-2, and the control cohort of children (matched 1:1 for age, gender, and week of testing) who tested negative for SARS-CoV-2.** The cohort of children with positive SARS-CoV-2 testing is presented here both as younger and older groups; and for usual (i.e., short) vs. extended illness duration.

	Children with positive SARS-CoV-2 test					Children with negative SARS-CoV-2 test (matched cohort)
	Younger group	Older group	Symptom duration <10 days	Symptom duration ≥ 28 days	Full cohort	
<b>Number</b>	588	1,146	1,183	77	1,734	1,734
<b>Males (%)</b>	287 (48.9)	577 (50.3)	618 (52.2)	35 (45.5)	864 (49.8)	865 (49.9)
<b>Age, years (median, [IQR])</b>	9 [7;10]	15 [13;16]	13 [10;15]	14 [12;16]	13 [10;15]	13 [10;15]
<b>BMI (kg/m<sup>2</sup>) (median, [IQR])</b>	17.0 [15.1;19.7]	20.1 [17.8;22.3]	19.0 [16.5;21.8]	18.6 [16.3;21.8]	19.2 [16.6;21.8]	19.0 [16.5;21.5]
<b>Asthma (%)</b>	69 (11.7)	147 (12.8)	134 (11.7)	10 (13.0)	216 (12.8)	229 (13.2)
<b>Visit to hospital (%)</b>	16 (2.7)	21 (1.8)	20 (1.7)	1 (1.3)	37 (2.1)	26 (1.5)

<b>Illness duration (median, [IQR])</b>	<b>5 [2;9]</b>	<b>7 [3;12]</b>	<b>4 [2;6]</b>	<b>46 [32;58]</b>	<b>6 [3;11]</b>	<b>3 [2;7]</b>
<b>Number of symptoms in the first week (median, [IQR])</b>	<b>3 [2;5]</b>	<b>4 [2;6]</b>	<b>3 [2;5]</b>	<b>6 [4;8]</b>	<b>3 [2;6]</b>	<b>2 [1;4]</b>

BMI: Body Mass Index. IQR: Inter Quartile Range.

**Table 2. Symptoms over the duration of illness in children testing positive for SARS-CoV-2.**


	Sample tested positive for SARS-CoV-2		
	Younger children (aged 5-11 years, n=588)	Older children (aged 12-17 years, n=1,146)	Overall cohort (n=1,734)
Headache	324	755	1,079 (62.2%)
Fatigue	258	696	954 (55.0%)
Sore Throat	213	585	798 (46.0%)
Anosmia	132	554	686 (39.6%)
Fever	257	396	653 (37.7%)
Abdominal Pain	163	194	357 (20.6%)
Dizziness	84	300	384 (22.1%)
Persistent Cough	145	298	443 (25.5%)
Loss of Appetite	120	254	374 (21.6%)
Eye Soreness	89	248	337 (19.4%)
Myalgias	54	231	285 (16.4%)
Nausea	95	193	288 (16.6%)
Hoarse voice	63	166	229 (13.2%)
Chest Pain	37	143	180 (10.4%)
Dyspnoea	24	143	167 (9.6%)
Diarrhoea	48	79	127 (7.3%)
Confusion	15	81	96 (5.5%)
Red Welts	16	36	52 (3.0%)
Blisters	4	22	26 (1.5%)

### **Figure 1. Flowchart of Inclusion and Exclusion Criteria for the Study.**


Legend: overall number for the entire cohort of children is given first; numbers within brackets separated by oblique refer to younger children and older children in that order. 'Not valid result' – PCR test result proxy-reported as "failed test" or "still waiting". 'Duration calculable' – illness onset within defined timeframe of testing for SARS-CoV-2, and with defined endpoint (for details, please see Methods). 'Irregular logging' – proxy-reporting with intervals of >7 days between proxy-reports during illness duration). 'Illness onset outside of study bounds' - symptom onset before 1 September 2020 or after 24 January 2021. 'Hosp' – presenting to hospital (either admitted to hospital or seen in Accident and Emergency ward).

[image at following page]

[caption at previous page]



**Figure 2. Prevalence of symptoms reported over the course of illness in younger (5-11 years, n=588) and older (12-17 years, n=1,146) children testing positive for SARS-CoV-2.**



**Figure 3. Median duration of each symptom [IQR] in younger (5-11 years) and older (12-17 years) children.**

